Amlodipine once-daily in systemic hypertension

被引:22
作者
Pfammatter, JP [1 ]
Clericetti-Affolter, C [1 ]
Truttmann, AC [1 ]
Busch, K [1 ]
Laux-End, R [1 ]
Bianchetti, MG [1 ]
机构
[1] Univ Bern, Inselspital, Dept Paediat, CH-3010 Bern, Switzerland
关键词
amlodipine; calcium channel blockers; childhood; cyclosporine; hypertension;
D O I
10.1007/s004310050897
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The calcium channel blocker nifedipine is widely used in children with systemic hypertension; however, because of the short duration of action, three to four daily doses of the standard preparation are required. Amlodipine once-daily, a calcium channel blocker structurally related to nifedipine with an excellent bioavailability and a long elimination half-time, has been shown to reduce blood pressure in adults. No information is available on the use of amlodipine in childhood. The effects of amlodipine once-daily (5 to 10 mg) were therefore assessed in 28 paediatric patients with hypertension. Amlodipine was withdrawn in five patients who experienced oedema and flushing. In the remaining 23 patients blood pressure was significantly reduced 3 weeks after amlodipine (on average by 7/5 mm Hg) and further decreased at 12 weeks (by 21/12 mm Hg). Heart rate and body weight were unchanged. In eight patients concomitantly treated with cyclosporine, the blood level of this agent was stable throughout the study, thus not requiring any dose adjustment.
引用
收藏
页码:618 / 621
页数:4
相关论文
共 50 条
  • [41] Interleukin-2 Profiles Shortly After Tacrolimus Conversion From a Twice-Daily to Once-Daily Regimen
    Mecule, A.
    Tinti, F.
    Bachetoni, A.
    Poli, L.
    D'Alessandro, M.
    Alessandri, C.
    Umbro, I.
    Nofroni, I.
    Berloco, P. B.
    Mitterhofer, A. P.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (04) : 1017 - 1019
  • [42] Effect of Conversion From Twice-daily to Once-daily Tacrolimus on Glucose Intolerance in Stable Kidney Transplant Recipients
    Tsuchiya, T.
    Ishida, K.
    Ito, S.
    Deguchi, T.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (01) : 118 - 120
  • [43] Pharmacokinetics in stable head transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations
    Alloway, Rita
    Vanhaecke, Johan
    Yonan, Nizar
    White, Michel
    Haddad, Haissam
    Rabago, Gregorio
    Tymchak, Wayne
    Molina, Beatriz Diaz
    Grimm, Michael
    Eiskjaer, Hans
    Karpf, Carmen
    Undre, Nasrullah
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (09) : 1003 - 1010
  • [44] The Effects of Amlodipine and S(-)-Amlodipine on Vascular Endothelial Function in Patients With Hypertension
    Si, Daoyuan
    He, Yuquan
    Yang, Chunyan
    Ni, Lujia
    Li, Bing
    Ding, Mei
    Yang, Ping
    AMERICAN JOURNAL OF HYPERTENSION, 2014, 27 (01) : 27 - 31
  • [45] Single-pill combination of amlodipine and valsartan in the management of hypertension
    Flack, John M.
    Hilkert, Robert
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (12) : 1979 - 1994
  • [46] Barnidipine, a novel calcium antagonist for once-daily treatment of hypertension: A multicenter, double-blind, placebo-controlled, dose-ranging study
    Hart, W
    Holwerda, NJ
    CARDIOVASCULAR DRUGS AND THERAPY, 1997, 11 (05) : 637 - 643
  • [47] Barnidipine, a Novel Calcium Antagonist for Once-Daily Treatment of Hypertension: A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study
    Wimpeter Hart
    Nicolas J. Holwerda
    Cardiovascular Drugs and Therapy, 1997, 11 : 637 - 643
  • [48] Heart rate-lowering and -regulating effects of once-daily sustained-release diltiazem
    Boden, WE
    Vray, M
    Eschwege, E
    Lauret, D
    Scheldewaert, R
    CLINICAL CARDIOLOGY, 2001, 24 (01) : 73 - 79
  • [49] ONCE DAILY COMPARED WITH TWICE DAILY ADMINISTRATION OF SLOW-RELEASE DILTIAZEM AS MONOTHERAPY FOR HYPERTENSION
    NIKKILA, M
    INKOVAARA, J
    HEIKKINEN, J
    ANNALS OF MEDICINE, 1991, 23 (02) : 141 - 145
  • [50] Is amlodipine the best initial a monotherapy for hypertension?
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (06) : 829 - 832